| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
81,110,000 |
| Market
Cap: |
2.07(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.62 - $29.18 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 21.5 |
| Insider 3/6 Months : 22.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Dyne Therapeutics is a muscle disease company focused on developing therapeutics for people living with genetically driven diseases. Co. is developing the following product candidates: DYNE-101, to address the genetic basis of myotonic dystrophy type 1 by targeting the toxic nuclear DMPK RNA that causes the disease; DYNE-251 for patients with mutations amenable to skipping Exon 51, to be followed by the development of therapeutics for patients with mutations amenable to skipping other exons, including Exon 53, 45 and 44; and DYNE-301 to address the genetic basis of facioscapulohumeral dystrophy by reducing DUX4 expression in muscle tissue.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,714,285 |
1,714,285 |
3,583,447 |
| Total Buy Value |
$0 |
$29,999,988 |
$29,999,988 |
$50,000,022 |
| Total People Bought |
0 |
1 |
1 |
3 |
| Total Buy Transactions |
0 |
1 |
1 |
3 |
| Total Shares Sold |
4,567,914 |
5,034,239 |
5,451,868 |
5,708,183 |
| Total Sell Value |
$110,613,784 |
$119,163,524 |
$124,434,495 |
$127,620,166 |
| Total People Sold |
9 |
9 |
9 |
9 |
| Total Sell Transactions |
50 |
72 |
93 |
103 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vida Ventures Ii-A, Llc |
10% Owner |
– – • |
2020-09-21 |
4 |
B |
$19.00 |
$15,485,000 |
I/I |
815,000 |
79,921 |
1.5 |
-8% |
|
| Vida Ventures Ii-A, Llc |
10% Owner |
– – • |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,145,046 |
57,916 |
|
- |
|
| Cureduchenne Ventures, Llc |
10% Owner |
– – • |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
602,972 |
602,972 |
|
- |
|
| Gadicke Ansbert |
10% Owner |
– – • |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
I/I |
4,951,303 |
91,081 |
|
- |
|
| Stehman-Breen Catherine |
Director |
– • – |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
10,725 |
115,713 |
|
- |
|
| Klein Lawrence Otto |
Director |
– • – |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
10,725 |
10,725 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
I/I |
7,638,511 |
1,608,785 |
|
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
1,608,785 |
1,608,785 |
|
- |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-09-21 |
4 |
B |
$19.00 |
$12,540,000 |
I/I |
660,000 |
2,805,045 |
1.5 |
-8% |
|
| Shah Rajeev M. |
10% Owner |
– – • |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,145,045 |
2,145,045 |
|
- |
|
| Hurwitz Edward |
Director |
– • • |
2020-09-21 |
4 |
A |
$0.00 |
$0 |
I/I |
4,951,303 |
91,081 |
|
- |
|
| High Susanna Gatti |
Chief Operating Officer |
• – – |
2020-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
35,904 |
35,904 |
|
- |
|
| Beskrovnaya Oxana |
See Remarks |
• – – |
2020-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
19,289 |
19,289 |
|
- |
|
| Subramanian Romesh |
Chief Scientific Officer |
• – • |
2020-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
41,309 |
566,249 |
|
- |
|
| Scalzo Richard William |
See Remarks |
• – – |
2020-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
11,465 |
11,465 |
|
- |
|
| Mcneill Jonathan |
See Remarks |
• – – |
2020-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
17,012 |
36,910 |
|
- |
|
| Brumm Joshua T |
See Remarks |
• • – |
2020-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
107,027 |
107,027 |
|
- |
|
| Atlas Venture Associates Opportunity I, Llc |
10% Owner |
– – • |
2020-09-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,110,404 |
|
- |
|
| Mcneill Jonathan |
See RemarksOfficer |
• – – |
2020-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
19,898 |
|
- |
|
| Stehman-Breen Catherine |
Director |
– • – |
2020-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
104,988 |
|
- |
|
| Rhodes Jason P |
Director |
– • • |
2020-09-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,110,404 |
|
- |
|
| Subramanian Romesh |
Chief Scientific OfficerOffice |
• – • |
2020-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
524,940 |
|
- |
|
222 Records found
|
|
Page 9 of 9 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.73 (2.95%) 
